|Bid||0.0000 x 800|
|Ask||0.0000 x 1000|
|Day's Range||2.9300 - 3.0180|
|52 Week Range||2.0000 - 3.9500|
|Beta (3Y Monthly)||-7.70|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Leslie Aberman, Vice President, Legal Affairs and Intellectual PropertySamantha Willing, Vice President, People SEATTLE, Sept. 19, 2019 -- Neoleukin Therapeutics, Inc..
SEATTLE, Sept. 05, 2019 -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de.